Ειδήσεις: REVENUE GUIDANCE | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

22/03 20:10 yahoo.com

Why Arm Holdings Stock Rallied This Week

Arm Holdings stock rally earnings beat revenue guidance AI chips mobile technology

19/03 16:39 yahoo.com

Investor Sells Off SaaS Stock Down 43% This Past Year Despite $1.7 Billion Revenue Guidance

SaaS stock decline investor sell-off revenue guidance market skepticism tech sector

19/03 10:05 investing.com

DocMorris targets EBITDA break-even in 2026 with new revenue guidance

DocMorris EBITDA break-even 2026 revenue guidance online pharmacy

17/03 15:34 yahoo.com

Delta, American Airlines hike revenue guidance as demand offsets fuel costs

Delta American Airlines revenue guidance fuel costs passenger demand profitability

17/03 13:54 marketwatch.com

Delta defies oil-price spike and boosts its revenue outlook as travel demand accelerates

Delta airline oil prices revenue guidance investor confidence stock surge

17/03 09:06 defenseworld.net

Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference

Exelixis cabozantinib zanzalintinib 2026 outlook revenue guidance oncology

17/03 09:06 defenseworld.net

Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference

Exelixis cabozantinib zanzalintinib 2026 outlook revenue guidance oncology

Loading...